Literature DB >> 1350491

Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.

T Wendt1.   

Abstract

In a randomized, double-blind study oral doses of 50 mg carvedilol (Dilatrend) were compared with 40 mg propranolol in 16 male patients with coronary heart disease, CHD [12 without significant stenoses following percutaneous transluminal coronary angioplasty (PTCA), 4 with multivessel disease]. Bicycle ergometry in the supine position was performed before and 80 min after drug application; measurements were done at rest, during and after exercise. Clinically, the total exercise time and the onset of angina and exhaustion were noted, while the investigated hemodynamic parameters were heart rate, systemic and pulmonary pressures and resistances, cardiac index, and lower limb blood flow. Clinically, carvedilol improved the exercise tolerance more than propranolol as regards angina and exhaustion. Hemodynamically, carvedilol did not lead, as the classic betablocker propranolol does, to an increase in systemic or pulmonary resistance, to a decrease in cardiac output, or to an increase of the pulmonary capillary wedge pressure during exercise, but instead caused opposite changes. In contrast to propranolol, the post exercise lower limb blood flow had increased significantly. The differences in action between the two betablockers can be explained by the vasodilating properties of carvedilol. Due to these acute effects, carvedilol may be preferred to propranolol in the treatment of CHD patients with hypertension, peripheral occlusive artery disease, and/or coronary vasospasm.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350491     DOI: 10.1007/bf00207618

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  29 in total

1.  Intermittent claudication complicating beta-blockade.

Authors:  J C Rodger; C D Sheldon; R A Lerski; W R Livingstone
Journal:  Br Med J       Date:  1976-05-08

2.  Hemodynamic effects of propranolol in coronary heart disease.

Authors:  J O Parker; R O West; S Di Giorgi
Journal:  Am J Cardiol       Date:  1968-01       Impact factor: 2.778

3.  Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients.

Authors:  R Eggertsen; L Andrén; R Sivertsson; L Hansson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease.

Authors:  M J Kern; P Ganz; J D Horowitz; J Gaspar; W H Barry; B H Lorell; W Grossman; G H Mudge
Journal:  Circulation       Date:  1983-06       Impact factor: 29.690

5.  Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties.

Authors:  K Strein; G Sponer; B Müller-Beckmann; W Bartsch
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

6.  Carvedilol for systemic hypertension.

Authors:  M E Heber; G S Brigden; M P Caruana; A Lahiri; E B Raftery
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

7.  [Influence of cold-stimuli on hemodynamics and coronary diameters. Provocation of coronary artery spasm].

Authors:  T Wendt; W Schulz; M Kaltenbach; G Kober
Journal:  Z Kardiol       Date:  1983-01

8.  The use of carvedilol in elderly hypertensive patients.

Authors:  T O Morgan; A Anderson; J Cripps; W Adam
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 9.  The role of multiple action agents in hypertension.

Authors:  P Lund-Johansen; P Omvik
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease.

Authors:  B Silke; G I Nelson; R C Ahuja; S H Taylor
Journal:  Br Heart J       Date:  1982-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.